Stifel Nicolaus Sticks to Its Buy Rating for Momenta Pharma (MNTA)
Stifel Nicolaus analyst Derek Archila reiterated a Buy rating on Momenta Pharma (MNTA) today. The company’s shares closed last Friday at $32.75, close to its 52-week high of $35.13.
According to TipRanks.com, Archila is a 4-star analyst with an average return of 5.3% and a 47.8% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Pacira Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Momenta Pharma with a $38.00 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $35.13 and a one-year low of $9.51. Currently, Momenta Pharma has an average volume of 1.14M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA.